PATIENT_ID,COHORT,CANCER_HISTOLOGY,REASON_OFF_TRIAL,LAB_TEST_VIRUS,BEST_OVERALL_RECIST,CB,BEST_RECIST_TM_TARGET,TARGETED_LESION_TM_EARLY,change_ctDNA,change_ctDNA_category,Pembrolizumab_sensitivity_groups_n71,OSevent,OSTIME_Months,OSTIME_Months_since_C3,PFSevent,PFSTIME_Months,PFSTIME_Months_since_C3,TMB_n72,TMB_category,TMB_ctDNA_category_n55INS-A-001,A: Head and Neck,Squamous cell carcinoma of tongue base,Progression,p16 positive,PD,0,27.3,27.3,,,,,,,,,,,,INS-A-002,A: Head and Neck,Squamous cell carcinoma of retromolar trigone,Clinical Progression,not tested,SD,0,5.7,5.7,0.25,increase from baseline,1. LS,1,6.54,5.13,1,2.76,1.35,1.7747,low-TMB,"low-TMB,increase from baseline"INS-A-003,A: Head and Neck,Squamous cell carcinoma of floor of mouth,Progression,none,PD,0,41.7,41.7,24.82,increase from baseline,1. LS,1,5.68,4.30,1,1.41,0.03,2.5114,low-TMB,"low-TMB,increase from baseline"INS-A-004,A: Head and Neck,Squamous cell carcinoma of floor of mouth,Study Completion,not tested,CR,1,-100,-44.8,,,,,,,,,,,,INS-A-007,A: Head and Neck,Squamous cell carcinoma of tongue base,Toxicity,p16 positive,PR,1,-100,-45.5,-0.94,decrease from baseline,4. HS,0,28.78,27.20,1,20.93,19.35,1.4543,low-TMB,"low-TMB,decrease from baseline"INS-A-008,A: Head and Neck,Squamous cell carcinoma of tongue base,Clinical Progression,p16 positive,PD,0,46.2,46.2,0.32,increase from baseline,1. LS,1,3.19,1.81,1,1.38,0.00,,,INS-A-010,A: Head and Neck,Squamous cell carcinoma of tonsil,Progression,p16 positive,SD,0,17.8,17.8,-0.31,decrease from baseline,3. MSPP,1,18.17,16.59,1,4.17,2.60,1.1213,low-TMB,"low-TMB,decrease from baseline"INS-A-011,A: Head and Neck,Squamous cell carcinoma of tongue ,Clinical Progression,none,SD,1,-27,-8.9,0.10,increase from baseline,2. MSER,1,17.12,15.74,1,8.71,7.33,,,INS-A-012,A: Head and Neck,Squamous cell carcinoma of soft palate,Toxicity,none,SD,0,-3.7,-3.7,4.29,increase from baseline,2. MSER,1,9.53,8.18,1,3.25,1.91,2.6786,low-TMB,"low-TMB,increase from baseline"INS-A-013,A: Head and Neck,Squamous cell carcinoma of oropharynx,Progression,not tested,SD,0,11,11,-0.12,,3. MSPP,1,7.85,6.54,1,3.91,2.60,,,INS-A-014,A: Head and Neck,Squamous cell carcinoma of hypopharynx,Withdrew consent,none,PD,0,39.5,39.5,,,,1,3.35,,1,1.91,,1.9391,low-TMB,INS-A-015,A: Head and Neck,Squamous cell carcinoma of hypopharynx/proximal esophagus,Death unexpected,none,SD,0,-13.5,-13.5,-0.80,decrease from baseline,4. HS,1,2.30,0.92,1,2.30,0.92,,,INS-A-018,A: Head and Neck,Squamous cell carcinoma of glottis,Intercurrent Ilness,none,SD,0,13.7,13.7,5.00,increase from baseline,1. LS,1,4.24,2.89,1,3.22,1.87,,,INS-A-019,A: Head and Neck,Squamous cell carcinoma of supraglottis and glottis,On treatment,none,PR,1,-60,-42.5,-0.96,decrease from baseline,4. HS,0,18.37,17.02,0,18.37,17.02,,,INS-A-020,A: Head and Neck,Squamous cell carcinoma of tongue,On treatment,none,CR,1,-100,10.9,-0.95,decrease from baseline,3. MSPP,0,18.66,17.28,0,18.66,17.28,,,INS-A-021,A: Head and Neck,Squamous cell carcinoma of tonsil,Clinical Progression,p16 positive,SD,0,7.3,7.3,0.11,increase from baseline,1. LS,1,8.74,7.39,1,2.76,1.41,3.5659,high-TMB,"high-TMB,increase from baseline"INS-A-023,A: Head and Neck,Squamous cell carcinoma of tonsil,Clinical Progression,p16 positive,PD,0,37.3,37.3,1.79,increase from baseline,1. LS,0,17.51,16.13,1,1.74,0.36,1.7013,low-TMB,"low-TMB,increase from baseline"INS-A-024,A: Head and Neck,Squamous cell carcinoma of oral cavity,Exceeding dosing window,none,PD,0,1.3,1.3,,,,,,,,,,2.22,low-TMB,INS-A-025,A: Head and Neck,Squamous cell carcinoma of soft pallate,Clinical Progression,none,NE,0,NE,,,,,1,0.56,,1,0.56,,,,INS-B-001,B: Breast,Triple negative breast cancer,Progression,none,SD,0,8.2,8.2,,,,,,,,,,,,INS-B-002,B: Breast,Triple negative breast cancer,Progression,none,PD,0,6.7,6.7,0.53,increase from baseline,1. LS,1,3.58,2.43,1,0.36,,1.7761,low-TMB,"low-TMB,increase from baseline"INS-B-003,B: Breast,Triple negative breast cancer,Progression,none,PD,0,-26.7,-26.7,0.51,increase from baseline,2. MSER,1,20.73,19.32,1,1.94,0.53,4.1188,high-TMB,"high-TMB,increase from baseline"INS-B-005,B: Breast,Triple negative breast cancer,Clinical Progression,none,PD,0,NE,,,,,1,2.56,,1,1.35,,,,INS-B-006,B: Breast,Triple negative breast cancer,Clinical Progression,none,PD,0,27.6,27.6,,,,,,,,,,,,INS-B-007,B: Breast,Triple negative breast cancer,Progression,none,PD,0,11.9,11.9,,,,,,,,,,,,INS-B-009,B: Breast,Triple negative breast cancer,Progression,none,PD,0,104.5,104.5,,,,1,4.07,,1,0.95,,,,INS-B-011,B: Breast,Triple negative breast cancer,Clinical Progression,none,SD,0,19.6,19.6,-0.34,decrease from baseline,3. MSPP,1,23.82,22.44,1,2.04,0.66,,,INS-B-014,B: Breast,Triple negative breast cancer,Progression,none,PD,0,2.9,2.9,12.28,increase from baseline,1. LS,1,14.29,12.98,1,1.87,0.56,2.6856,high-TMB,"high-TMB,increase from baseline"INS-B-015,B: Breast,Triple negative breast cancer,Progression,none,PD,0,1.5,1.5,3.70,increase from baseline,1. LS,1,4.67,3.29,1,1.64,0.26,1.2342,low-TMB,"low-TMB,increase from baseline"INS-B-016,B: Breast,Triple negative breast cancer,On treatment,none,PR,1,-66,-31.4,,,,,,,,,,,,INS-B-017,B: Breast,Triple negative breast cancer,Toxicity,none,SD,0,-29,-29,-0.95,decrease from baseline,4. HS,0,23.98,22.64,1,5.45,4.11,,,INS-B-018,B: Breast,Triple negative breast cancer,Progression,none,PD,0,81.6,81.6,,,,1,3.19,,1,1.74,,,,INS-B-019,B: Breast,Triple negative breast cancer,Progression,none,PD,0,25,25,,,,1,10.51,,1,1.48,,4.0175,high-TMB,INS-B-020,B: Breast,Triple negative breast cancer,Progression,none,PD,0,25.7,25.7,3.54,increase from baseline,1. LS,1,6.31,4.93,1,1.71,0.33,3.2351,high-TMB,"high-TMB,increase from baseline"INS-B-021,B: Breast,Triple negative breast cancer,Progression,none,PD,0,13.8,13.8,-0.19,decrease from baseline,3. MSPP,1,11.50,10.12,1,1.61,0.23,1.3254,low-TMB,"low-TMB,decrease from baseline"INS-B-022,B: Breast,Triple negative breast cancer,Progression,none,PD,0,12.2,12.2,1.36,increase from baseline,1. LS,1,19.98,18.53,1,1.94,0.49,3.7487,high-TMB,"high-TMB,increase from baseline"INS-B-023,B: Breast,Triple negative breast cancer,Progression,none,PD,0,6.3,6.3,0.02,increase from baseline,1. LS,1,7.72,6.34,1,1.94,0.56,3.2354,high-TMB,"high-TMB,increase from baseline"INS-B-024,B: Breast,Triple negative breast cancer,Progression,none,PD,0,76.5,76.5,-0.25,decrease from baseline,3. MSPP,1,8.64,7.26,1,1.91,0.53,1.5082,low-TMB,"low-TMB,decrease from baseline"INS-B-026,B: Breast,Triple negative breast cancer,Progression,none,PD,0,28,28,,,,1,9.00,,1,0.92,,1.8826,low-TMB,INS-B-027,B: Breast,Triple negative breast cancer,Clinical Progression,none,NE,0,NE,,,,,1,0.72,,1,0.56,,1.989,low-TMB,INS-B-028,B: Breast,Triple negative breast cancer,Clinical Progression,none,PD,0,11.8,11.8,,,,0,9.72,,1,0.76,,3.3147,high-TMB,INS-C-001,C: Ovary,"Ovarian, high grade serous",Progression,none,SD,0,18,18,-0.47,decrease from baseline,3. MSPP,0,35.38,34.07,1,3.78,2.46,1.3026,low-TMB,"low-TMB,decrease from baseline"INS-C-002,C: Ovary,"Ovarian, high grade serous",Toxicity,none,SD,0,18.8,18.8,,,,1,20.80,,1,2.27,,1.7112,low-TMB,INS-C-003,C: Ovary,"Ovarian, high grade serous",Toxicity,none,SD,0,-6.8,-6.8,,,,0,35.19,,1,5.26,,1.5796,low-TMB,INS-C-004,C: Ovary,"Ovarian, high grade serous",Progression,none,SD,1,-15,-11.8,0.96,increase from baseline,2. MSER,1,7.95,6.60,1,5.98,4.63,3.5758,high-TMB,"high-TMB,increase from baseline"INS-C-005,C: Ovary,"Ovarian, high grade serous",Toxicity,none,SD,0,8.6,8.6,,,,1,3.32,,1,1.08,,2.4561,low-TMB,INS-C-006,C: Ovary,"Ovarian, high grade serous",Progression,none,PD,0,-19.8,-19.8,-0.52,decrease from baseline,4. HS,1,24.02,22.67,1,2.14,0.79,2.9327,high-TMB,"high-TMB,decrease from baseline"INS-C-007,C: Ovary,"Ovarian, high grade serous",Progression,none,PD,0,22,22,,,,1,5.16,,1,0.92,,,,INS-C-008,C: Ovary,"Ovarian, high grade serous",Progression,none,PD,0,32.3,32.3,,,,,,,,,,,,INS-C-009,C: Ovary,"Ovarian, high grade serous",Clinical Progression,none,SD,0,-12.1,-12.1,,,,,,,,,,,,INS-C-010,C: Ovary,"Ovarian, high grade serous",Progression,none,PD,0,29.8,29.8,1.25,increase from baseline,1. LS,1,13.90,12.29,1,1.81,0.20,,,INS-C-011,C: Ovary,"Ovarian, high grade serous",Progression,none,PD,0,-7.3,-7.3,,,,1,3.81,,1,1.15,,1.4282,low-TMB,INS-C-013,C: Ovary,"Ovarian, high grade serous",Progression,none,PD,0,3.8,3.8,0.68,increase from baseline,1. LS,1,27.47,26.15,1,1.81,0.49,1.388,low-TMB,"low-TMB,increase from baseline"INS-C-015,C: Ovary,"Ovarian, high grade serous",Progression,none,PD,0,11,13.5,,,,,,,,,,,,INS-C-017,C: Ovary,"Ovarian, high grade serous",Progression,none,PD,0,38.7,38.7,-0.95,decrease from baseline,3. MSPP,0,25.07,23.59,1,1.97,0.49,1.0458,low-TMB,"low-TMB,decrease from baseline"INS-C-018,C: Ovary,"Ovarian, high grade serous",Progression,none,SD,1,-26,15,-0.53,decrease from baseline,3. MSPP,0,29.70,28.35,1,10.55,9.20,1.6867,low-TMB,"low-TMB,decrease from baseline"INS-C-020,C: Ovary,"Ovarian, high grade serous",Progression,none,PD,0,26.2,26.2,5.17,increase from baseline,1. LS,0,28.32,26.74,1,1.81,0.23,2.3921,low-TMB,"low-TMB,increase from baseline"INS-C-021,C: Ovary,"Ovarian, high grade serous",Progression,none,PD,0,23.9,23.9,,,,1,4.04,,1,0.66,,1.6361,low-TMB,INS-C-022,C: Ovary,"Ovarian, high grade serous",Progression,none,PD,0,NE,,,,,1,9.79,,1,0.89,,1.6813,low-TMB,INS-C-023,C: Ovary,"Ovarian, high grade serous",Progression,none,PD,0,11.4,11.4,-0.77,decrease from baseline,3. MSPP,0,27.17,25.82,1,1.84,0.49,1.6988,low-TMB,"low-TMB,decrease from baseline"INS-C-024,C: Ovary,"Ovarian, high grade serous",Progression,none,PD,0,12.5,12.5,2.04,increase from baseline,1. LS,1,4.37,3.02,1,1.81,0.46,1.8802,low-TMB,"low-TMB,increase from baseline"INS-C-025,C: Ovary,"Ovarian, high grade serous",Toxicity,none,PD,0,31.9,31.9,,,,1,14.32,,1,1.84,,,,INS-D-001,D: Melanoma,"Melanoma, desmoplastic",Clinical Progression,none,PR,1,-42,-15.6,-0.28,decrease from baseline,4. HS,0,32.92,31.57,1,23.23,21.88,,,INS-D-002,D: Melanoma,"Melanoma, choroidal",Clinical Progression,none,NE,0,NE,,,,,1,1.05,,1,0.72,,0.5715,low-TMB,INS-D-003,D: Melanoma,"Melanoma, NOS",Study Completion,none,PR,1,-83,-36.2,-1.00,decrease from baseline,4. HS,0,30.82,29.47,0,30.82,29.47,17.2509,high-TMB,"high-TMB,decrease from baseline"INS-D-004,D: Melanoma,"Melanoma, superficial spreading",Study Completion,none,PR,1,-100,-47.1,-0.79,decrease from baseline,4. HS,0,30.75,29.44,0,30.75,29.44,4.117,high-TMB,"high-TMB,decrease from baseline"INS-D-005,D: Melanoma,"Melanoma, NOS",Intercurrent Ilness,none,PR,1,-100,-26,-1.00,decrease from baseline,4. HS,0,28.78,27.43,0,28.78,27.43,39.891,high-TMB,"high-TMB,decrease from baseline"INS-D-006,D: Melanoma,"Melanoma, NOS",Study Completion,none,PR,1,-66,-23.4,-0.31,decrease from baseline,4. HS,0,29.21,27.89,1,16.16,14.85,7.7265,high-TMB,"high-TMB,decrease from baseline"INS-D-007,D: Melanoma,"Melanoma, NOS",Progression,none,PD,0,31,31,0.68,increase from baseline,1. LS,1,6.14,4.76,1,1.87,0.49,8.6116,high-TMB,"high-TMB,increase from baseline"INS-D-008,D: Melanoma,"Melanoma, NOS",Progression,none,PD,0,37.5,37.5,10.66,increase from baseline,1. LS,1,6.44,4.40,1,1.91,,5.4427,high-TMB,"high-TMB,increase from baseline"INS-D-009,D: Melanoma,"Melanoma, mucosal vaginal ",Study Completion,none,PR,1,-100,-42.7,-1.00,decrease from baseline,4. HS,0,26.22,24.90,0,26.22,24.90,0.9633,low-TMB,"low-TMB,decrease from baseline"INS-D-011,D: Melanoma,"Melanoma, superficial spreading",Progression,none,PD,0,NE,,-0.67,decrease from baseline,,1,3.52,2.10,1,1.58,0.16,,,INS-D-012,D: Melanoma,"Melanoma, NOS",On treatment,none,PR,1,-86,-48.3,,,,0,21.59,20.30,0,21.59,20.30,6.1696,high-TMB,INS-D-013,D: Melanoma,"Melanoma, NOS",On treatment,none,CR,1,-82,-51.5,-0.15,decrease from baseline,4. HS,0,17.48,16.07,0,17.48,16.07,7.39,high-TMB,"high-TMB,decrease from baseline"INS-E-001,E: Mixed,"Sarcoma, granular cell",Progression,none,PD,0,22.9,22.9,0.11,increase from baseline,1. LS,1,20.14,18.79,1,1.91,0.56,0.5387,low-TMB,"low-TMB,increase from baseline"INS-E-002,E: Mixed,"Sarcoma, hemangiopericytoma",Clinical Progression,none,SD,1,8,9.8,-0.86,decrease from baseline,3. MSPP,1,4.96,3.61,1,4.96,3.61,0.6631,low-TMB,"low-TMB,decrease from baseline"INS-E-003,E: Mixed,"Adenocarcinoma of endocervix, mucinous type",Progression,HPV positive,SD,0,18.1,18.1,0.11,increase from baseline,1. LS,1,22.60,21.22,1,4.44,3.06,3.9263,high-TMB,"high-TMB,increase from baseline"INS-E-004,E: Mixed,"Sarcoma, solitary fibrous tumor",Investigator's Decision,none,SD,1,-0.7,-0.7,#DIV/0!,increase from baseline,2. MSER,0,35.42,34.04,0,35.42,34.04,1.024,low-TMB,"low-TMB,increase from baseline"INS-E-005,E: Mixed,"Nasopharyngeal carcinoma, non-keratinizing",Progression,EBV,PD,0,NE,,0.27,increase from baseline,,1,3.15,1.77,1,1.91,0.53,0.9841,low-TMB,"low-TMB,increase from baseline"INS-E-006,E: Mixed,Endometrioid adenocarcinoma of endometrium,Progression,none,PD,0,78.3,78.3,,,,1,3.42,,1,0.76,,,,INS-E-007,E: Mixed,"Squamous cell carcinoma of maxillary sinus, spindle cell type",Progression,none,SD,1,0,11.8,-0.99,decrease from baseline,3. MSPP,1,17.84,16.49,1,6.01,4.67,,,INS-E-008,E: Mixed,"Nasopharyngeal carcinoma, non-keratinizing",Clinical Progression,EBV,SD,1,0,16.6,-0.71,decrease from baseline,3. MSPP,1,14.26,12.88,1,7.85,6.47,1.0342,low-TMB,"low-TMB,decrease from baseline"INS-E-011,E: Mixed,"Sarcoma, clear cell",Progression,none,PD,0,71.2,71.2,2.84,increase from baseline,1. LS,1,3.25,1.87,1,2.04,0.66,0.7649,low-TMB,"low-TMB,increase from baseline"INS-E-012,E: Mixed,Small cell carcinoma of anus,Progression,,PD,0,34,34,2.27,increase from baseline,1. LS,1,13.96,12.58,1,1.91,0.53,1.439,low-TMB,"low-TMB,increase from baseline"INS-E-013,E: Mixed,Merkle cell carcinoma,Intercurrent Ilness,MCPyV,CR,1,-97,-12.2,0.18,increase from baseline,2. MSER,0,32.10,30.72,0,32.10,30.72,0.4721,low-TMB,"low-TMB,increase from baseline"INS-E-015,E: Mixed,"Sarcoma, alveolar",Withdrew consent,none,NE,NA,NE,,,,,,,,,,,,,INS-E-016,E: Mixed,Large cell neuroendocrine carcinoma of cervix,Progression,,PD,0,64.7,64.7,8.50,increase from baseline,1. LS,1,13.96,12.62,1,1.94,0.59,1.6857,low-TMB,"low-TMB,increase from baseline"INS-E-018,E: Mixed,Adenocarcinoma of GEJ,Progression,none,PD,0,27,27,1.18,increase from baseline,1. LS,0,28.19,26.64,1,1.87,0.33,6.1484,high-TMB,"high-TMB,increase from baseline"INS-E-019,E: Mixed,Clear cell carcinoma of endometriosis (MSS),Progression,none,PD,0,25,25,44.09,increase from baseline,1. LS,0,29.34,27.96,1,1.87,0.49,1.4198,low-TMB,"low-TMB,increase from baseline"INS-E-020,E: Mixed,Merkle cell carcinoma,Clinical Progression,MCPyV,PR,1,-34,-15.5,-0.41,decrease from baseline,4. HS,1,25.33,23.92,1,8.05,6.64,,,INS-E-021,E: Mixed,Squamous cell carcinoma of penis,Progression,none,PD,0,22,22,0.78,increase from baseline,1. LS,1,3.84,2.00,1,1.97,0.13,1.8984,low-TMB,"low-TMB,increase from baseline"INS-E-022,E: Mixed,Merkle cell carcinoma,Toxicity,MCPyV,PR,1,-65,-48.4,-0.99,decrease from baseline,4. HS,1,18.99,17.58,1,10.09,8.67,10.3857,,INS-E-023,E: Mixed,Squamous cell carcinoma of anus/rectum,Progression,,PD,0,44.6,44.6,0.47,increase from baseline,1. LS,1,4.80,3.42,1,1.87,0.49,1.4557,low-TMB,"low-TMB,increase from baseline"INS-E-024,E: Mixed,Adenoid cystic carcinoma,Progression,none,SD,0,9.5,9.5,-0.03,decrease from baseline,3. MSPP,1,8.18,6.80,1,3.94,2.56,0.9149,low-TMB,"low-TMB,decrease from baseline"INS-E-025,E: Mixed,Adenocarcinoma of colon (MSI),Progression,none,PD,0,14.2,14.2,0.40,increase from baseline,1. LS,1,7.89,6.51,1,1.94,0.56,24.7084,high-TMB,"high-TMB,increase from baseline"INS-E-026,E: Mixed,Basal cell and squamous cell poorly differentiated carcinoma,Toxicity,none,PR,1,-89,-84.4,-1.00,decrease from baseline,4. HS,0,25.92,24.54,0,25.92,24.54,187.0235,high-TMB,"high-TMB,decrease from baseline"INS-E-027,E: Mixed,Chondrosarcoma,Progression,none,PD,0,0,0,2.35,increase from baseline,2. MSER,1,9.69,8.31,1,1.84,0.46,,,INS-E-028,E: Mixed,Adenocarcinoma of colon (MSI),Intercurrent Ilness,none,PR,1,-98,-19.5,-1.00,decrease from baseline,4. HS,0,25.20,21.98,0,25.20,21.98,13.3395,,INS-E-029,E: Mixed,Endometrioid adenocarcinoma of endometrium,Progression,none,SD,0,15.5,15.5,19.69,increase from baseline,1. LS,0,24.80,23.46,1,3.94,2.60,1.3916,low-TMB,"low-TMB,increase from baseline"INS-E-030,E: Mixed,Myxoid liposarcoma,Progression,none,PD,0,34.2,34.2,16.77,increase from baseline,1. LS,1,13.73,12.35,1,1.91,0.53,0.797,low-TMB,"low-TMB,increase from baseline"INS-E-031,E: Mixed,Adenocarcinoma from biliary system (cholangiocarcinoma),Progression,none,PD,0,9.7,9.7,2.26,increase from baseline,1. LS,0,9.49,8.15,1,1.94,0.59,,,INS-E-032,E: Mixed,Adenoid cystic carcinoma,Progression,none,SD,1,2,2,-0.93,decrease from baseline,3. MSPP,0,24.80,23.43,1,13.60,12.22,0.5772,low-TMB,"low-TMB,decrease from baseline"INS-E-033,E: Mixed,Merkle cell carcinoma,Progression,MCPyV,PD,0,10.1,10.1,,,,1,2.37,,1,1.15,,0.7018,low-TMB,INS-E-034,E: Mixed,Merkle cell carcinoma,Progression,MCPyV,PD,0,150,150,6.48,increase from baseline,1. LS,1,5.78,4.40,1,1.87,0.49,1.5426,low-TMB,"low-TMB,increase from baseline"INS-E-035,E: Mixed,Merkle cell carcinoma,Progression,MCPyV,PD,0,33,33,-0.29,decrease from baseline,3. MSPP,0,18.83,17.41,1,1.87,0.46,0.8029,low-TMB,"low-TMB,decrease from baseline"INS-E-036,E: Mixed,Neuroendocrine tumor of pancreas,Progression,none,SD,0,6,6,,,,,,,,,,,,